These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 21051706)

  • 1. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion.
    Sacu S; Pemp B; Weigert G; Matt G; Garhofer G; Pruente C; Schmetterer L; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3046-50. PubMed ID: 21051706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
    Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
    Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in retinal blood flow in patients with macular edema secondary to branch retinal vein occlusion before and after intravitreal injection of bevacizumab.
    Nagaoka T; Sogawa K; Yoshida A
    Retina; 2014 Oct; 34(10):2037-43. PubMed ID: 24896136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
    Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
    Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
    Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
    Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
    Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
    JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
    Lim JW
    Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in areas of capillary nonperfusion after intravitreal injection of bevacizumab in eyes with branch retinal vein occlusion.
    Terui T; Kondo M; Sugita T; Ito Y; Kondo N; Ota I; Miyake K; Terasaki H
    Retina; 2011 Jun; 31(6):1068-74. PubMed ID: 21451440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
    Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
    Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
    Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
    Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes.
    Campochiaro PA; Hafiz G; Channa R; Shah SM; Nguyen QD; Ying H; Do DV; Zimmer-Galler I; Solomon SD; Sung JU; Syed B
    Ophthalmology; 2010 Dec; 117(12):2387-2394.e1-5. PubMed ID: 20630595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
    Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
    Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
    Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
    Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB; Yau L; Hoang C; Tuomi L
    Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
    Chang LK; Spaide RF; Klancnik JM; Sorenson J; Slakter JS; Freund KB; Yannuzzi LA; Tseng JJ; Klein R
    Retina; 2011 May; 31(5):821-8. PubMed ID: 21317833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration.
    Hosseini H; Lotfi M; Esfahani MH; Nassiri N; Khalili MR; Razeghinejad MR; Nouri-Mahdavi K
    Retina; 2012 May; 32(5):967-71. PubMed ID: 22146127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age-related macular degeneration.
    Bonnin P; Pournaras JA; Makowiecka K; Krivosic V; Kedra AW; Le Gargasson JF; Gaudric A; Levy BI; Cohen YS; Tadayoni R; Massin P
    Acta Ophthalmol; 2014 Aug; 92(5):e382-7. PubMed ID: 25043792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Intravitreal Ranibizumab on Vessel Functionality in Patients With Retinal Vein Occlusion.
    Corvi F; La Spina C; Benatti L; Querques L; Lattanzio R; Bandello F; Querques G
    Am J Ophthalmol; 2015 Jul; 160(1):45-52.e1. PubMed ID: 25896458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.